Extended Data Fig. 7: β-glucan mediated protection depends on trained neutrophils.
From: β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus
(a) FACS plots showing the depletion of neutrophils in the blood of mice treated with anti-LY6G depletion antibody based on Ly6G and CD11b expression. (b) FACS plots showing the depletion of neutrophils based on FSC/SSC back gating. (c-g) WT and Ccr22-/- mice were treated with β-glucan. Frequency and absolute number of monocytes and neutrophils in the BM (c, d); blood (e); and lungs (f, g) at day 4 post β-glucan treatment (n = 4, data pooled from two individual experiments). (h-j) C57BL/6 (WT and Ccr2-/-) mice were infected with IAV (lethal dose) at day 7 post β-glucan treatment. Weight loss (i) and survival (j) was monitored over time (n = 10). (k) Adoptive transfer of CD45.1 neutrophils confirmed in the lungs of CD45.2 recipient mice. (l-m) IFNARflox x Mrp8Cre mice were treated with β-glucan for 4 days, frequency and total cell counts of LKS+ cells (m, n), GMPs (o, p) and GPs (q, r) were quantified in the BM (n = 4). Data represented as mean ± SEM. Data were analyzed using two-tailed unpaired t-test (m-r) or two-way ANOVA followed by Sidak’s multiple comparisons tests (c-g, i). Survival was monitored by a log-rank test (j). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Illustrations in h and l created using BioRender.com.
